The importance o f folate in norm al fetal developm ent and wellbeing has been recognized only during the past three decades and knowledge concerned is still far from complete. In m an, folate acts as a substrate in the transfer of one-carbon moieties and thereby, plays an essential role in the synthesis o f several am ino acids such as m ethionine and nucleic acids. Consequently, folate require ments are related to the am ount of tissue growth. Epidemiological, clinical and teratological research showed that this B-vitamin is particularly involved in the prevention and pathogenesis o f neural tube defects. Therefore, in this review the metabolism o f folate has been outlined. Furtherm ore, the characteristics of the various genically determ ined folate 'deficiencies5 as well as a possible biochemical explanation o f the relationship between folate and neural tube defects are being discussed. Finally, the new recommen dations launched in N ovem ber 1993 by the D utch H ealth Council as well as the Food and N utrition Council with regard to folate supplementation in the prevention o f neural tube defects are presented. may explain (in part) the beneficial effect o f folate sup plementation in the prevention o f NTDs. Finally, new recommendations regarding folate supplementation are presented.
Introduction
Maternal folate status is important in the prevention and pathogenesis of neural tube defects (NTDs) [1] . It is, however, unclear which precise mechanisms are in volved. Pregnant women are prone to develop a folate deficiency, probably due to their increased folate demands for the growing fetal and maternal tissues. Other factors provoking folate deficiency include a poor diet, the physiological haemodilution o f pregnancy, in creased plasma clearance and hormonal influences [2] , Our hypothesis is that a subset o f NTDs might be due to a disbalance in the maternal and/or embryonic homocysteine metabolism, partly genically determined, in which folate plays a particularly important role [3, 4] . Therefore, in the first part of this review, attention is given to the biochemistry and daily requirements o f folate, the diagnosis of folate deficiency and the genetic disorders in folate metabolism. In the second part, a possible underlying mechanism will be described which The structure of folic acid and its derivatives (modified from Rosenblatt [9] ). sidechains, i.e. mono and oligoglutamates, and in part as larger molecules, i.e. polyglutamates. Folates are present in all body tissues. Folate is stored to the great est extent in the polyglutamate form in liver, pancreas, kidneys and brain. Mono and oligoglutamates (free folate) and polyglutamates together represent 'total folate'.
Biochemistry o f folate
Transport mechanism. The absorption process of dietary folate (mainly as 5-methylpteroylpolyglutamates) is divided in two steps (Fig. 2) . In the first step, polyglutamates are converted to monoglutamates by a conjugase present in the jejunum. Only monoglutamates or, at most oligoglutamate derivatives are taken up by The stored THF-polyglutamates can be degraded to THF-monoglutamates by intracellular conjugase and released into the circulation. 5-methyl-THF-monoglutamate is the predominant form o f folate in serum and in many tissues. In the liver, polyglutamate derivatives o f 5-methyl-THF are the major stored folates.
About two-thirds of 5-methyl-THF in serum is loose ly bound to a non-specific low-affinity folate binder such as albumin. A second folate binder has also been described. Although this binder has a high affinity for * folate, its capacity is low. This protein may represent a storage form [6] . Blood of the umbilical cord contains both low and high-affinity folate binders [7] , Folate binding proteins are involved in the transfer o f folate against a concentration gradient from the mother to the fetus, which suggests active placental transport by which the fetus is able to accumulate folate. Strelling [8] deter mined higher folate levels in fetal blood as compared with maternal blood. The placenta seems able to supply the fetus with adequate folate. However, little is known about folate provision for the growth of the conceptus before the placenta has developed.
Metabolism. The prime function o f folate is to provide one-carbon moieties for the synthesis of three of the four bases of DNA, i.e. guanine, adenine and thymine, as well as for synthesis o f other compounds. These one-carbon moieties are formate required for the synthesis o f the purines 5-formamidoimidazole-4-carboxamide ribo nucleotide (FAICAR) and formylglycinamide ribonuc leotide (FGAR), methylene for deoxythymidine synthesis (dTMP), and the methyl group for methionine synthesis [9, 10] , The one-carbon moiety is derived from the con version of serine into glycine, formiminoglutamic acid (FiGlu) into glutamic acid (Glu), or the cleavage o f gly cine. The folate metabolism in man is depicted in Fig, 3 .
The vitamin B 12-dependent enzyme 5-methyl-THFhomocysteine methyl-transferase or methionine synthase (EC 2.1.
1.13) catalyses the conversion o f 5-methyl-THF and homocysteine into THF and methionine. Methionine reacts with adenosine to form S-adenosylmethionine. S-Adenosylmethionine is the most important methyl donor and regulates its own synthesis by inhibition o f 5,10methylene-THF reductase (EC 1.1.1.68) and stimulation of cystathionine synthase (EC 4.2.1.22) [11].
Methionine synthase requires reduced vitamin B12, i.e. methylcobalamin, as a cofactor. Cobalamin accepts its methyl group from 5-methyl-THF [12] . Both folate and vitamin B12 deficiency will decrease methionine forma tion which may result in decreased levels of »S-adenosylmethionine. In methylcobalamin deficiency, folate is trapped as 5-methyl-THF because methionine synthase is the only reaction able to convert 5-methyl-THF into THF (methy 1-folate trap) [13] . In such cases, a function al folate deficiency exists, although normal to increased folate levels will be present in blood.
Requirements
Humans are totally dependent on dietary sources o f folate, and major contributors are green leafy be met by a variety o f folate derivatives, as long as the essential structure o f pteroylglutamic acid remains in tact [14] , The inactivation of folate occurs after oxida tion and exposure to ultraviolet light and heat. Thus, naturally occurring folates are lost in storage and cook ing. Most naturally occurring folates are present as polyglutamates. This is in contrast to pharmaceutically available folate, which contains only monoglutamates. In the gut, monoglutamates are absorbed much faster than poly glutamates.
The demand o f folate is increased in infancy, adoles cence and pregnancy. The recommended dietary intakes for folate are presented in Table 1 .
Diagnosis o f folate deficiency
Folate deficiency leads to clinical symptoms such as di arrhoea, cheilosis and glossitis [15] .
The haematological manifestations o f folate deficiency are macrocytosis, low reticulocyte, leucocyte and platelet count, anisocytosis, poikilocytosis, macroovalocytes and hypersegmentation o f the nucleus o f the neutrophils. Pathological cir cumstances, resulting in an increased folate requirement are: malabsorption due to sprue, restoration of blood cells after loss or haemolysis, alcohol abuse, treatment with folate antagonists (methotrexate) and antiepileptic drugs (phenytoin, phenobarbital, primidone).
Different methods are available for the measurement o f folates. However, they are difficult to compare. Serum folate concentrations vary rather widely with respect to nutrition, sex, and the use of drugs. Folate is incorporated into red cells during erythropoiesis. Therefore, red cell polyglutamates reflect a more accurate and less variable index of folate status than serum folate levels [16] .
Mor phologic blood examination showing hypersegmentation o f the polymorphonuclear leucocyte nucleus, used to be the best way to diagnose a folate deficiency [14]. Func tion tests to determine folate status include the deoxyuridine suppression test and the FiGlu function test.
Both methods are used to study folate levels indirectly.
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vegetables, liver and kidney. Requirements of folate can The deoxyuridine suppression test is based on the obser vation that, in case o f folate deficiency, the uptake of tritiated thymidine by bone marrow cells is suppressed because o f decreased folate-dependent conversion o f DUM P into DTMP. The FiGlu function test is based on the increased urinary excretion of FiGlu after histidine loading, because folate deficiency leads to a decreased conversion of FiGlu into glutamic acid (Glu) (Fig. 3) [17].
In addition, folate deficiency will result in a mild to moderate hyperhomocysteinaemia. Therefore, the deter mination o f the concentration of total homocysteine in blood seems to be a valid indirect method, as well to diag nose a metabolic folate deficiency [18, 19] . 
Genetic disorders of folate metabolism
Up to now, five inherited disorders of folate metabo lism have been described. These are: (a) 5,10-methylene-THF reductase deficiency; (b) functional 5-methyl-THFhomocysteine methyltransferase (methionine synthase) de ficiency; (c) glutamate formiminotransferase deficiency;
(d) hereditary folate malabsorption; and (e) dihydrofolate reductase deficiency. Their clinical and biochemical characteristics are summarized in Table 2 . 5,10-methylene-THFreductase deficiency. Mudd et al, [21] first described 5,10-methylene-THF reductase defi ciency. About 30 patients have been described (Fig. 3 , conversion 4 and Table 2 ). The severity of the enzyme deficiency and the corresponding level of 5-methyl-THF parallels the clinical and biochemical symptoms. Clini cal symptoms are: generalized seizures, delayed psychomotor development and peripheral neuropathy. Severely affected patients often die at infancy or early childhood [22] , Patients with milder symptoms tend to survive into adult life [21] . Their typical laboratory fea- tures are given in Table 2 . The enzyme defect is inherited in an autosomal recessive trait and can be assessed in liver, fibroblasts, lymphocytes and leukocytes. Kang et al. [23] recently discovered a 'new variant' of 5,10-methylene-THF reductase deficiency, which is characterized by the absence of neurological abnormalities, an enzyme activ ity of about 50% of the normal value, and distinctive ther molability of the enzyme in lymphocytes. Reportedly, the incidence of thermolabile 5,10-methylene-THF reductase was 5% in controls and 17% in patients with coronary artery disease. This suggests a high mutated gene frequen cy among the general p op u lation . The m ild hyperhomocysteinaemia assessed in some subjects with thermolabile 5,10-methylene-THF reductase was effective ly treated by oral folic acid therapy. Because severe 5,10methylene-THF reductase deficiency is resistant to folate treatment, betaine is often prescribed. Functional methionine synthase deficiency. Vitamin B |2 as methylcobalamin is an essential cofactor for methionine synthase, and as adenosylcobalamin for the enzyme methylmalonyl-CoA mutase (EC 5.4.99.2). Therefore, an enzymatic disorder in the synthesis o f these cobalamins will lead to a functional defect in methionine synthase or methylmalonyl-CoA mutase activity (Fig. 3, conversion  5 and Table 2 Table 2 .
). The reported enzymatic defects may af fect either methylcobalamin synthesis (cobalamin E and G mutation), the synthesis o f adenosylcobalamin (cobalamin A and B mutation), or both (cobalamin C, D and F mutation). The biochemical characteristics are shown in
Glutamate formiminotransferase deficiency. The enzyme glutamate formiminotransferase (EC 2.1.2.5) is involved in the catabolism o f histidine (Fig. 3, conversion 9 and Table 2 ). This pathway may be present only in liver and kidneys, and represents, quantitatively, a minor singlecarbon-pool, Glutamate formiminotransferase deficien cy syndrome, an autosomal recessively inherited disease, can be divided into two different phenotypes. The severe type is probably caused by a primary block in the cyclodeaminase enzyme (Fig. 3, conversion 10) . These pa tients suffer from mental and physical retardation and cortical atrophy. The milder type of the disease may be due to a defect in the glutamate formiminotransferase enzyme (Fig. 3, conversion 9 
and Table 2) without symp toms of mental retardation [9]. Folate, vitamin-Bi2 or serine treatment is hardly influencing biochemical symp toms such as FiGlu excretion and formiminoglutamic acidaemia. At present, the determination o f enzyme ac tivity is only possible in hepatocytes.
Defective folate absorption. An autosomal recessive in herited disorder in the absorption of folate was first described by Luhby et al. (Figs. 2 and 3, conversion 1 and Table 2 ) [24] . About a dozen patients have been reported, who fail to absorb oral fo lic acid monoglutamates or reduced folates (food) [9, 14] . These folate malabsorption disorders support the existence o f a specific carrier mechanism in the transport of folate across the intestinal wall, and into the cerebrospinal fluid. The common clinical presentation in hereditary folate malabsorption is megaloblastic anaemia, diarrhoea, mouth ulcers, severe physical and mental retardation, and seizures in the first few months o f life. Some patients re spond to treatment with very large doses o f folic acid monoglutamate (up to 40 mg/day). In others, the vitamin was successfully given intramuscularly. Some showed very low folate levels in the cerebrospinal fluid possibly due to a transport defect from the serum into the cerebrospinal fluid. Intramuscular treatment with reduced folates such as 5-formyl-THF (folinic acid (0Leucovorin)) can pro duce neurologic improvement [9] .
Dihydrofolate reductase deficiency. A rare inherited dis order, dihydrofolate reductase deficiency, has been reported in three cases (Fig. 3, conversion 2) . Depending on the degree of enzyme deficiency, this disease presents in infancy and may result in stillbirths and spontaneous abortions during reproductive life [25, 26] , Clinical symp toms of surviving infants are: failure to thrive, severe megaloblastic anaemia, glossitis, mental retardation and splenic enlargement. The diagnosis is based primarily on low hepatic levels o f dihydrofolate reductase activity. Treatment with ®Leucovorin bypasses the enzyme block and corrects the defect.
Neural-tube defects

In 1952, Thiersch first suggested an association between NTDs and a maternal lack of folate, due to the prenatal use o f folate antagonists [27]. Hibbard [17] reported a higher prevalence of birth defects in the offspring of folate-deficient mothers (3%), judged by an increased urinary excretion o f FiGlu after histidine loading, com pared to controls (1.6%). However, the difference was not statistically significant and the malformations did not in clude NTDs. In 1965, Hibbard and Smithells reported a possible link between folate deficiency and the develop ment of human fetal malformations, in particular central nervous system malformations, including N T D s [28]. Their results suggested the presence o f an underlying defect of folate metabolism, such as a disturbance in folate absorption or turnover, possibly precipitated by the in creased demands o f folate during pregnancy. This has been supported by Yates et al. [29] who demonstrated an association between maternal folate levels and N T D births, which could not be entirely explained by a lower
intake of folate. Because the red cell folate levels in par ticular were lowest in mothers who had three or four pre vious N TD pregnancies, they hypothesized that a maternal genetic disorder of folate metabolism was re sponsible for the development o f NTDs. The data reported by Kirke et al. [30] are in line with this. They found that maternal plasma folate and vitamin B 12 lev els, determined at the first antenatal visit, were indepen dent risk factors for having a child with a NTD.
The N TD prevalence in the products of spontaneous abortion is 10-fold increased as compared to the preva lence at birth [31] . Regarding this, it is of interest, that already in 1964, a possible relationship was demonstrated by Hibbard [17] between the occurrence of spontaneous abortion and folate deficiency.
As it can be concluded that a maternal shortage of folate during the periconceptional period may play a role in the development of NTDs, maternal folate supplemen tation in early pregnancy might therefore be a preven tive measure against the development of NTDs. Several observational studies have been carried out, most of which showed the protective effect of an increased maternal folate intake by dietary measures or tablets [32] [33] [34] [35] [36] . These studies have been extensively reviewed previously [1] , Finally, the intervention studies, summarized and presented in Table 3 , definitely proved the beneficial effect of an increased maternal folate intake in the periconcep tional period on the first occurrence and recurrence risk of NTDs [37-41], Women taking antiepileptic drugs for the treatment of epilepsy have an increased risk o f having an infant with a congenital malformation, particularly NTD [42] . Mead ow [43] speculated that the teratogenicity of antiepilep tic drugs may reside in the induction o f folate deficiency . This is supported by the relationship between the use of antiepileptic drugs, folate levels and adverse pregnancy outcome, including spontaneous abortions and congenital malformations [44] . Antiepileptic drugs such as phéno barbital, phenytoin and primidone can reduce folate lev els by inhibiting intestinal absorption, or by increasing folate turn-over due to induction of the cytochrome P-450 glucuronyl transferase enzymes [45, 46] . The mater nal use o f valproic acid and carbamazepine is considered to increase the risk of spina bifida in particular [47, 48] , For both antiepileptic drugs, no strong evidence is avail able for the presence of abnormally low serum folate lev els, but several studies report some form of interference with folate metabolism [49, 50] . Recently, in mice, it has been demonstrated that valproic acid interferes with the conversion o f THF into 5-formyl-THF, which is possibly due to inhibition of the enzyme glutamate formyltransferase, through which the teratogenicity of val proic acid may be explained by an altered folate metabolism [49] ,
In case a lack of maternal folate in early pregnancy predisposes to the development of NTDs, these malfor mations might be prevented by folic acid supplementa tion. Biale and Lewenthal [51] prescribed folic acid tablets to epileptic women using antiepileptic drugs and found a reduced risk of congenital malformations. However, there have been some criticisms regarding this study, i.e. historical controls were used, no tests of compliance were incorporated, and several women participated more than once.
Although folate is generally accepted as non-toxic in man, high-dose folic acid supplementation may have several disadvantages. A high dose of folic acid (> 1.0 mg folic acid per day) may mask the haematologic effects of vitamin B 12 deficiency, while its neurologic manifesta tions progress [52] . Possible risks of a high level of circu lating folate are noted by Scott and Weir [13] . Folic acid is a neurotoxin and causes convulsions in laboratory ani mals. Although the blood/brain barrier normally restricts access of folic acid in such a way that very high doses are required to produce these effects, similar toxicity oc curs at much lower doses if the blood/brain barrier is damaged. In epileptic women, therefore, supplementation of folic acid with doses similar to that used in the MRC trial [40] , might result in increased seizure frequency [53] . As the developed brain may be protected from the neurotoxic effects of synthetic folic acid by the blood/brain barrier, it is unknown whether neural tissue during very early embryonic development is protected. A low dose of folic acid may also be favourable, as it is unclear whether a high-dose folate interferes with the transfer and metabolism o f zinc in man, especially in cases with a marginal zinc status [54] . This may be important as dietary zinc deficiency and a relative shortage o f ma ternal zinc has been associated with NTDs in human [55] , Furthermore, the findings o f Quinn et al. [56] suggest that in the presence of a zinc deficiency, the administration of high-dose folate increases the teratogenicity o f such a deficiency. The enzyme, 7-glutamyl hydrolase, converts polyglutamates to monoglutamates, which is an impor tant step in the absorption of folate. Its activity is zincdependent, which may be another regulatory mechanism in the availability of folate [57],
A possible biochemical explanation
the study was performed. The metabolism of homocys teine was studied by performing a standardized oral methionine loading test [4] , In addition, vitamin levels, as well as biochemical parameters, were measured. The study was performed on the 21st day of the ovulatory cycle, because one o f our previous studies showed changes in the metabolism of homocysteine during the normal ovulatory cycle [61] . The fasting homocysteine concentrations revealed to be lowest during the midluteal period, and therefore screening on a disorder in the metabolism of homocysteine is most sensitive dur ing this period of the cycle. Therefore, all studies were performed at the midluteal phase o f the cycle.
The results revealed that in 22% of the women, who had given birth to an infant with a N TD , methionine in tolerance was present after excluding folate and other vi tamin deficiencies, and liver or renal disturbances. Therefore, a maternal disorder in the metabolism of homocysteine strongly suggests being a risk factor for having an infant with anencephalus or spina bifida.
Because folate treatment without the existence of a folate deficiency increases the conversion o f homocys teine into methionine, a certain percentage of the pre vention of NTDs, through folate supplementation, might be mediated by this beneficial effect upon homocysteine metabolism. Finally, to gain more infor mation about the association o f maternal hyperhomocysteinaemia with the ocurrence of NTDs, we determined the homocysteine and relevant vitamin con centrations in amniotic fluid and blood of mothers car rying a child with a N TD , and compared those with a control group. Increased homocysteine levels in amnio tic fluid were found in women carrying a child with a NTD (Steegers-Theunissen et al, in press), which con firms the data of our previous study.
In future, further investigation is needed to study the possible toxic effects o f increased homocysteine and decreased methionine levels on the formation of the neu ral tube. Apart from that, the remethylation enzymes, especially those involved in folate and vitamin B ]2 me tabolism, have to be investigated in methionineintolerant women. Then, we might be able to further prevent the occurrence o f these congenital malforma tions in the future,
Recommendations
At the beginning o f this decade, two intervention studies definitely proved the beneficial effect of maternal folate supplementation to prevent the first occurrence and recurrence risk o f a NTD-child [40, 41] . Therefore, the Dutch Health Council as well as the Food and Nu trition Council were necessitated to launch new recom mendations with regard to the improvement of periconceptional maternal folate status [62] . The Dutch Council distinguishes between women who had had a child with a NTD and therefore have a recurrence risk, and those who did not previously have a NTD-affected child and therefore have an occurrence risk. Women with a NTD family history, those who suffer from diabetes, or using drugs interfering with folate metabo lism and those who have a normal population risk are belonging to the latter category.
In order to significantly reduce the recurrence risk of a NTD-affected child, women are being advised to take a daily folate supplements of 4 -5 mg from at least 4 weeks before conception until at least 8 weeks after con ception. This should be done under medical supervision. It is recommended that women with an occurrence risk should take care of a daily folate intake of 400 fig from at least 4 weeks before conception until at least 8 weeks after conception, The consumption of foods which are rich in folate is encouraged in order to reach this level Introduction as soon as possible, of foods which have been fortified or restored with folate, is also recom mended. The choice of foods to which folate has been enriched and the amount added should be such that there is as little chance as possible of an intake in excess of 1 mg/day, If the introduction of such food-products cannot be achieved within a reasonable period of time, women are advised to take one 400 fig folate tablet daily,
The proposed measures to increase folate intake will have to be evaluated after a certain period, in order to determine their effect on public health.
